(Bloomberg) — Advanced imaging that detects plaque in the brain should be covered by Medicare and private insurers for select people with dementia to help diagnose or rule out Alzheimer’s disease, advocates and doctors say.

The recommendations released today are the first to help govern the burgeoning field of brain imaging and may increase the use of the practice to improve care for the 5 million Americans affected with Alzheimer’s. The Alzheimer’s Association and the Society of Nuclear Medicine and Molecular Imaging crafted the proposal to address which patients might benefit from the PET scan technology that detects the plaque.

While amyloid plaque is a hallmark of Alzheimer’s disease, not everyone with it has the mind-robbing condition. PET scans require a drug injected into patients to highlight the plaque for doctors. Eli Lilly & Co.’s Amyvid is the only compound currently approved for use with PET scans for this purpose.

“This is going to become much more ubiquitous and available over the next few years,” says Maria Carrillo, vice president of medical and scientific relations at the Chicago-based Alzheimer’s Association. “It’s something physicians can refer their patients for if they need additional information.”

Lilly’s drug isn’t now covered by Medicare, though the agency plans a hearing on Wednesday. Products from General Electric Co., Piramal Enterprises Ltd. and Navidea Biopharmaceuticals Inc. are expected to reach the market in the next two years.

The costs of the scans vary depending on where they are done and who conducts them, though prices for standard PET imaging range from $1,000 to $3,000.

Alzheimer’s is the sixth-leading cause of death in the U.S., according to the Alzheimer’s Association. The number of people with the disease is expected to double within 20 years as the world’s population ages, to as many as 65.7 million people in 2030 and 115 million by 2050, the Geneva-based World Health Organization said last April. There is no treatment to cure or slow the disease. Current therapies address only symptoms.

While Alzheimer’s is the most common cause of dementia in the elderly, memory problems may also stem from drug side effects, strokes, thyroid problems and vitamin deficiencies.

The guidelines identify three groups of patients who should have insurance access to the brain imaging technology, the two organizations said. People with unexplained, worsening memory loss or confusion, those with possible Alzheimer’s disease who have unusual symptoms and those with progressive dementia that develops before the age of 65 may benefit, they say.

Register or login for access to this item and much more

All Employee Benefit News becomes archived within a week of it being published

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access